iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, announced today that it will present a poster at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo, May 2-5.
Rachel Jordan, PhD, a senior product manager at iBio, will present the poster (#P061), titled "Plant-Made Antibodies Show Superior Glycosylation Homogeneity While Retaining Pharmacokinetic Properties," which highlights:
- The production of a single uniform G0 glycosylation pattern, lacking fucose and xylose, of NISTmAb and rituximab when compared to Chinese Hamster Ovary (CHO) cell culture produced antibodies, which contain more heterogeneous glycosylation patterns.
- Comparability of in vivo rodent pharmacokinetic profiles for NISTmAb and rituximab produced using mammalian cell culture and the FastPharming System.
- How rapid, scalable transient expression in plants of high-quality mAbs for in vivo studies can significantly shorten the time to achieve in vivo proof-of-concept.
More information about producing consistent, high-quality antibodies in the FastPharming System may be accessed in a whitepaper here.
About iBio, Inc.
iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the FastPharming Manufacturing System; the ability to produce mAbs containing more heterogeneous glycosylation patterns as compared to other manufacturing systems; and producing mAbs that are comparable in vivo rodent pharmacokinetic profile as compared to other manufacturing systems. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to build a scalable manufacturing process using the Company’s FastPharming System; and the other factors discussed in the Company’s filings with the SEC including the Company’s Annual Report on Form 10-K for the year ended June 30, 2021 and the Company’s subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Released May 2, 2022